Treatment with lumateperone was associated with a statistically significantly longer time to relapse compared with placebo. Topline results were announced from a phase 3 trial evaluating lumateperone ...

Fred D. Lublin, MD, discusses evolving concepts in MS, including earlier high-efficacy therapy, unrecognized progression, and ...

“Our data add and expand previous observations on silent progression in MS and are consistent with the view of the disease as a single continuum, in which RAW [relapse-associated worsening] and PIRA ...

The efficacy and safety of CAPLYTA (lumateperone) as a maintenance treatment in adults with schizophrenia was demonstrated in a randomized withdrawal trial The study demonstrated a statistically ...

PRINCETON, NJ, September 26, 2025 (EZ Newswire) -- Opioid addiction, including dependence on substances such as fentanyl and heroin, is widely acknowledged as a global public health and social safety ...